

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

四川科倫博泰生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6990)

CHANGE OF JOINT COMPANY SECRETARY, AUTHORIZED REPRESENTATIVE AND PROCESS AGENT; AND CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG

RESIGNATION OF JOINT COMPANY SECRETARY, AUTHORIZED REPRESENTATIVE AND PROCESS AGENT

The board (the “**Board**”) of directors (the “**Director(s)**”) of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “**Company**”) hereby announces that Ms. Fung Wai Sum (“**Ms. Fung**”) has resigned as (i) a joint company secretary of the Company (“**Joint Company Secretary(ies)**”); (ii) an authorized representative of the Company (the “**Authorized Representative**”) under Rule 3.05 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”); and (iii) an authorized representative of the Company for the acceptance of service of process and notices on behalf of the Company in Hong Kong (“**Process Agent**”) under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the “**Companies Ordinance**”) and Rule 19A.13(2) of the Listing Rules with effect from January 1, 2025.

Ms. Wong Wai Yee, Ella (“**Ms. Wong**”) has also resigned as a Process Agent under Part 16 of the Companies Ordinance with effect from January 1, 2025.

Ms. Fung and Ms. Wong has each confirmed to the Board that she does not have any disagreement with the Board and there are no other matters with respect to her resignation that need to be brought to the attention of the shareholders of the Company or the Stock Exchange.

APPOINTMENT OF JOINT COMPANY SECRETARY, AUTHORIZED REPRESENTATIVE AND PROCESS AGENT

Following the resignation of Ms. Fung, the Board is pleased to announce that Mr. Chung Ming Fai (“**Mr. Chung**”) has been appointed as (i) the Joint Company Secretary; (ii) the Authorized Representative; and (iii) the Process Agent under Part 16 of the Companies Ordinance and Rule 19A.13(2) of the Listing Rules with effect from January 1, 2025 in place of Ms. Fung. Mr. Zhou Zejian (“**Mr. Zhou**”), will continue to serve as the other Joint Company Secretary.

The biographical details of Mr. Zhou are as follows:

Mr. Zhou was appointed as the chief financial officer of the Company and the secretary of the Board in August 2022 and was then appointed as joint company secretary of the Company in January 2023. He is mainly responsible for the management of finance, capital market and securities affairs of the Company. From February 2022 to June 2022, he served as a non-executive Director of the Company, which was designated by IDG Capital, a pre-IPO investor of the Company.

Mr. Zhou has been engaged in investing, investing bank, capital market and medical industry for nearly 20 years. Prior to joining the Company, he worked in IDG Capital, Goldman Sachs (China) Securities Company Limited (高盛(中國)證券有限責任公司), China International Capital Corporation Limited (中國國際金融股份有限公司) and J.P. Morgan First Capital Securities Co., Ltd. (第一創業摩根大通證券有限責任公司).

Mr. Zhou obtained his master's degree in finance and bachelor's degree in financial management from Renmin University of China (中國人民大學).

The biographical details of Mr. Chung are as follows:

Mr. Chung is a senior vice president of SWCS Corporate Services Group (Hong Kong) Limited and has over 20 years of experience in corporate secretary, mergers and acquisitions, financial reporting and auditing. Mr. Chung is currently a fellow of the Hong Kong Institute of Certified Public Accountants and a member of CPA Australia. He obtained his bachelor's degree in commerce from the Australian National University in Australia.

WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

Reference is made to the waiver (the “**Waiver**”) granted to the Company by the Stock Exchange from strict compliance with the requirements of Rules 3.28 and 8.17 of the Listing Rules in respect of the eligibility of Mr. Zhou to act as a Joint Company Secretary for a three-year period from the date of the Company's listing (i.e. July 11, 2023) (the “**Waiver Period**”), on the condition that Mr. Zhou would be assisted by Ms. Fung, who possesses the qualification required under Rule 3.28 of the Listing Rules, during the Waiver Period. Relevant details of the Waiver were disclosed in the prospectus of the Company dated June 29, 2023. Given the condition of the Waiver could no longer be fulfilled following the resignation of Ms. Fung, the Company has applied to the Stock Exchange and the Stock Exchange has granted a new waiver (the “**New Waiver**”) to the Company from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules, for the remaining period of the Waiver Period (the “**Remaining Waiver Period**”) in relation to Mr. Zhou's eligibility to act as the Joint Company Secretary on the conditions that:

- (i) Mr. Zhou must be assisted by Mr. Chung during the Remaining Waiver Period; and
- (ii) the New Waiver could be revoked if there are material breaches of the Listing Rules by the Company.

Before the end of the Remaining Waiver Period, the Company must demonstrate and seek the Stock Exchange's confirmation that Mr. Zhou, having had the benefit of Mr. Chung's assistance during the Remaining Waiver Period, has attained the relevant experience and is capable of discharging the functions of a company secretary under Rule 3.28 of the Listing Rules such that a further waiver will not be necessary.

The Board would like to take this opportunity to express its appreciation to Ms. Fung for her valuable contributions during her tenure of office with the Company and extend its welcome to Mr. Chung on his new appointment.

CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG

The Board hereby also announces that the address of the principal place of business in Hong Kong of the Company will be changed to 40th Floor, Dah Sing Financial Centre, No. 248 Queen's Road East, Wanchai, Hong Kong with effect from January 1, 2025.

By order of the Board
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
LIU Gexin
Chairman of the Board and Non-executive Director

Hong Kong, December 6, 2024

As at the date of this announcement, the Board comprises Mr. LIU Gexin as the chairman of the Board and non-executive Director, Dr. GE Junyou as executive Director, Mr. LIU Sichuan, Mr. LAI Degui, Mr. FENG Hao, Mr. ZENG Xuebo and Mr. LI Dongfang as non-executive Directors, and Dr. ZHENG Qiang, Dr. TU Wenwei, Dr. JIN Jinping, and Dr. LI Yuedong as independent non-executive Directors.